Compare Amgen, Inc. (AMGN) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Tenet Healthcare Corporation — how do they compare? Amgen, Inc. trades at $363.66 (market cap $196.12B), while Tenet Healthcare Corporation trades at $204.25 (market cap $17.59B). The key difference: Amgen, Inc. is far larger — about 11.1× Tenet Healthcare Corporation's market cap, and Amgen, Inc. pays a 2.77% dividend while Tenet Healthcare Corporation pays none. Which is the better fit depends on your goals.
| AMGN | THC | |
|---|---|---|
Market Cap | $196.12B | $17.59B |
Sector | Health | Health |
52-Week High | $388.16 | $244.80 |
52-Week Low | $271.18 | $148.38 |
Enterprise Value | $241.41B | $27.84B |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Tenet Healthcare (THC) trades at $204.25, down 1.22% amid broader market weakness. The stock maintains strong fundamentals with a P/E of 10.62 and robust profitability metrics including 37.87% ROE. Recent quarterly earnings have consistently beaten expectations, with Q1 2026 EPS of $4.82 surpassing the $4.17 estimate. Technical indicators show bullish momentum despite overbought RSI readings, with support at $204 and resistance at $209.
The outlook remains positive with 81% analyst buy ratings and a $233.63 consensus price target representing 14% upside. Key risks include healthcare regulatory pressures and execution challenges in outpatient expansion. Earnings growth from the Ambulatory Care segment and defensive positioning during geopolitical tensions provide catalysts for continued appreciation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
